title: Dendritic cells: On the move from bench to bedside.
abstract: As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.
authors: Department of Dermatology, University of Zürich Medical School, Zürich, Switzerland.
authors: F O
authors: FO
authors: Nestle
authors: J
authors: J
authors: Banchereau
authors: D
authors: D
authors: Hart
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D011786:Quality Control
chemical_list: D019496:Cancer Vaccines